ジェネリック医薬品の世界市場：適応症 (中枢神経系・循環器・泌尿器・腫瘍・呼吸器・その他)・投与経路・流通チャネル・地域別 (～2035年)

世界のジェネリック医薬品の市場規模は、年率9.36%の着実な成長により、2035年までに約3倍の1兆1,485億5,000万米ドルに達すると予想されています。

慢性疾患の増加は、世界のジェネリック医薬品市場の成長に大きく寄与している要因とされています。がん、心疾患、てんかんや関節炎などの疾患が急増しており、低コストの治療が求められています。ジェネリック医薬品はブランド薬と同等の治療効果を、より安価に提供できるため、予算が厳しい患者や医療システムにとって唯一の選択肢となる場合があります。参入事業者は、新製品の投入、既存施設の拡張、新しい治療領域への進出などにより供給を強化しています。

一方で、品質や安全性の問題による自主的な製品リコールは、製品の供給やジェネリック医薬品への信頼にとって依然として大きな障害です。また、医療従事者のブランド薬への忠誠心も普及を制限する要因であり、慣れ親しんだブランド薬を処方し続けるケースも少なくありません。

同時に、研究開発への投資によって高品質なジェネリック薬の製造が可能となり、先端技術の導入や市場拡大につながっています。世界的な人口高齢化も重要な要因であり、慢性疾患の治療薬需要を支える高齢者は市場の大きな割合を占めています。2050年までにアジア太平洋地域の高齢人口は現在の2倍になると予測されており、安価な医薬品が最重要課題となるでしょう。これらの傾向に加え、政府の支援的な政策が続けば、ジェネリック医薬品は今後も世界の医療提供において最前線に立ち続けると考えられます。

地域分析

北米では、医療費の高騰を抑える必要性がジェネリック医薬品市場を支えています。米国は広範な製造ネットワークと、特許満了やジェネリック代替を可能にする明確な法制度により地域のリーダーです。患者のジェネリック薬受容度が高まっており、特に循環器科、腫瘍科、抗生物質の分野で強い販売実績を支えています。カナダのコスト効率を重視する医療政策も、ジェネリック薬の普及を安定的に後押ししています。

欧州市場は、明確な規制環境と、公的医療制度による低価格重視の姿勢から恩恵を受けています。ドイツ、スペイン、英国が主要な消費国であり、各国の医療サービスはジェネリック薬の処方を推進しています。医薬品へのアクセス性の向上と中間層人口の増加が、東欧諸国の需要拡大を後押ししています。競争力ある価格設定と支援的な法制度が、地域の成長要因です。

アジア太平洋は最も急成長している地域であり、その大部分はインドや中国の製造力によって牽引されています。インドは高品質のジェネリック薬を最も合理的な価格で供給する世界的リーダーであり、中国も大規模な医療改革の恩恵を受けています。人口構造の変化や慢性疾患の増加により、安価な薬剤への需要が高まっています。韓国やタイも含め、医療費削減のためにジェネリック薬を積極的に利用する国が増えています。

当レポートでは、世界のジェネリック医薬品の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

• 促進要因
  • 世界中で慢性疾患の発生率が増加
  • 参入企業による戦略的取り組みの高まり
  • 手頃な価格の医薬品への需要の高まり
• 抑制要因
  • 参入企業による自主的な製品リコール
  • ブランドロイヤルティと医師の嗜好
• 機会
  • ジェネリック医薬品の研究開発への投資
  • 高齢化人口の増加

第5章 市場要因分析

• ポーターのファイブフォースモデル
• COVID-19が世界のジェネリック医薬品市場に与える影響

第6章 世界のジェネリック医薬品市場：適応症別

• 概要
• 中枢神経系 (CNS)
• 心血管
• 泌尿器
• 腫瘍
• 呼吸器
• その他

第7章 世界のジェネリック医薬品市場：投与経路別

• 概要
• 経口
• 局所
• 非経口
• その他

第8章 世界のジェネリック医薬品市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 世界のジェネリック医薬品市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • その他
• 世界のその他の地域
  • 中東
  • アフリカ
  • 南米

第10章 競合情勢

• 市場シェア分析
• 競合ダッシュボード
• 公開企業の株式：サマリー
• 比較分析：主要企業の財務動向
• 主な展開・成長戦略

第11章 企業プロファイル

• SUN PHARMACEUTICAL INDUSTRIES LTD.
• LUPIN PHARMACEUTICALS, INC.
• ENDO INTERNATIONAL PLC
• AUROBINDO PHARMA
• ASPEN HOLDINGS
• CIPLA LTD
• NOVARTIS AG
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• FRESENIUS SE & CO. KGAA
• VIATRIS INC.

第12章 データの引用

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 3 GLOBAL GENERIC DRUGS MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2019-2035 (USD BILLION)
• TABLE 4 GLOBAL GENERIC DRUGS MARKET, FOR CARDIOVASCULAR, BY REGION, 2019-2035 (USD BILLION)
• TABLE 5 GLOBAL GENERIC DRUGS MARKET, FOR UROLOGY, BY REGION, 2019-2035 (USD BILLION)
• TABLE 6 GLOBAL GENERIC DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019-2035 (USD BILLION)
• TABLE 7 GLOBAL GENERIC DRUGS MARKET, FOR RESPIRATORY, BY REGION, 2019-2035 (USD BILLION)
• TABLE 8 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 10 GLOBAL GENERIC DRUGS MARKET, FOR ORAL, BY REGION, 2019-2035 (USD BILLION)
• TABLE 11 GLOBAL GENERIC DRUGS MARKET, FOR TOPICAL, BY REGION, 2019-2035 (USD BILLION)
• TABLE 12 GLOBAL GENERIC DRUGS MARKET, FOR PARENTERAL, BY REGION, 2019-2035 (USD BILLION)
• TABLE 13 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 14 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 15 GLOBAL GENERIC DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019-2035 (USD BILLION)
• TABLE 16 GLOBAL GENERIC DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019-2035 (USD BILLION)
• TABLE 17 GLOBAL GENERIC DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019-2035 (USD BILLION)
• TABLE 18 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019-2035 (USD BILLION)
• TABLE 19 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
• TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 23 US GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 24 US GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 25 US GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 26 CANADA GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 27 CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 28 CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 29 EUROPE: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
• TABLE 30 EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 31 EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 32 EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 33 GERMANY: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 34 GERMANY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 35 GERMANY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 36 FRANCE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 37 FRANCE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 38 FRANCE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 39 UK: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 40 UK: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 41 UK: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 42 ITALY: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 43 ITALY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 44 ITALY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 45 SPAIN: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 46 SPAIN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 47 SPAIN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 48 REST OF EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 49 REST OF EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 50 REST OF EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 51 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
• TABLE 52 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 53 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 54 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 55 CHINA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 56 CHINA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 57 CHINA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 58 INDIA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 59 INDIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 60 INDIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 61 JAPAN: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 62 JAPAN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 63 JAPAN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 64 SOUTH KOREA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 65 SOUTH KOREA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 66 SOUTH KOREA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 67 AUSTRALIA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 68 AUSTRALIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 69 AUSTRALIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 70 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 71 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 72 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 73 REST OF THE WORLD: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
• TABLE 74 REST OF THE WORLD: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 75 REST OF THE WORLD: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 76 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 77 MIDDLE EAST: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 78 MIDDLE EAST: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 79 MIDDLE EAST: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 80 AFRICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 81 AFRICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 82 AFRICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 83 SOUTH AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
• TABLE 84 SOUTH AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 85 SOUTH AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 86 PUBLIC PLAYERS STOCK SUMMARY
• TABLE 87 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• TABLE 88 PRODUCT LAUNCH
• TABLE 89 PRODUCT LAUNCH/ PRODUCT APPROVAL
• TABLE 90 EXPANSION
• TABLE 91 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED
• TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
• TABLE 93 LUPIN PHARMACEUTICALS, INC.: PRODUCT OFFERED
• TABLE 94 LUPIN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
• TABLE 95 ENDO INTERNATIONAL PLC: PRODUCT OFFERED
• TABLE 96 ENDO INTERNATIONAL PLC: KEY DEVELOPMENTS
• TABLE 97 AUROBINDO PHARMA: PRODUCT OFFERED
• TABLE 98 AUROBINDO PHARMA: KEY DEVELOPMENTS
• TABLE 99 ASPEN HOLDINGS: PRODUCT OFFERED
• TABLE 100 CIPLA LTD.: PRODUCTS OFFERED
• TABLE 101 CIPLA LTD.: KEY DEVELOPMENTS
• TABLE 102 NOVARTIS AG: PRODUCTS OFFERED
• TABLE 103 NOVARTIS AG: KEY DEVELOPMENTS
• TABLE 104 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED
• TABLE 105 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
• TABLE 106 FRESENIUS SE & CO. KGAA: PRODUCT OFFERED
• TABLE 107 FRESENIUS SE & CO. KGAA: KEY DEVELOPMENTS
• TABLE 108 VIATRIS INC.: PRODUCT OFFERED
• TABLE 109 VIATRIS INC.: KEY DEVELOPMENTS

LIST OF FIGURES

• FIGURE 1 GLOBAL GENERIC DRUGS MARKET: STRUCTURE
• FIGURE 2 GLOBAL GENERIC DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035)
• FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
• FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
• FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENERIC DRUGS MARKET
• FIGURE 6 GLOBAL GENERIC DRUGS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
• FIGURE 7 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2024 & 2035 (USD BILLION)
• FIGURE 8 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY INDICATION, 2024
• FIGURE 9 GLOBAL GENERIC DRUGS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
• FIGURE 10 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD BILLION)
• FIGURE 11 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024
• FIGURE 12 GLOBAL GENERIC DRUGS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
• FIGURE 13 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD BILLION)
• FIGURE 14 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024
• FIGURE 15 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019 & 2035 (USD BILLION)
• FIGURE 16 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY REGION, 2024
• FIGURE 17 NORTH AMERICA MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2035 (USD BILLION)
• FIGURE 18 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 19 NORTH AMERICA: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2024
• FIGURE 20 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 21 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 22 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 23 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 24 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 25 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 26 GENERIC DRUGS MARKET PLAYERS: COMPETITIVE ANALSIS, 2024
• FIGURE 27 COMPETITOR DASHBOARD: GLOBAL GENERIC DRUGS MARKET
• FIGURE 28 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
• FIGURE 30 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 31 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS
• FIGURE 32 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 33 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 34 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 35 CIPLA LTD.: FINANCIAL OVERVIEW
• FIGURE 36 CIPLA LTD.: SWOT ANALYSIS
• FIGURE 37 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 38 NOVARTIS AG: SWOT ANALYSIS
• FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
• FIGURE 41 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 42 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

Global Generic Drugs Market Research Report by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration (Oral, Topical, Parenteral, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and by Region (North America, Europe, Aia-Pacific, Rest of the World) Forecast till 2035

Industry Overview

The global generic drugs market is expected to nearly triple to USD 1,148.55 billion by 2035, driven by steady annual growth of 9.36%. A generic drug is a pharmaceutical product equivalent in dosage, strength, safety, and intended use to a branded medicine but sold under its chemical name. These drugs are typically marketed after patent protection ends, making them a cost-effective option for patients and healthcare systems.

The prevalence of chronic illnesses has been identified as a significant factor contributing to the growth of the global generic medication market. Cancer, heart disease, and other conditions like these have increased dramatically, and this is the case with the rise of epilepsy and arthritis, resulting in the need for low-cost treatment. Generic medicines deliver therapeutic benefits similar to those of branded drugs but at a much lower price; therefore, they become the only option for patients and healthcare systems that face difficult situations with their budgets. The players of the market are intensifying their supply by launching new products, extending their existing facilities, and entering into new therapeutic areas.

Nevertheless, voluntary product recalls caused by quality or safety issues remain a major obstacle to the availability of products and confidence in generics. Brand loyalty of healthcare professionals is one of the factors that limits wider adoption. Those who have not changed their minds still continue prescribing the branded medicines that they are familiar with to the patients.

At the same time, the act of allocating money to R&D allows the production of high-quality generics, which includes the implementation of advanced technology and the expansion of the market reach. The increasing age of the world population is one of the key factors that pushes up senior consumers, who make up a large portion of the market for chronic disease medication. By 2050, the old people in the Asia-Pacific is expected to be twice as many as they are now; therefore, affordable medicines will be the topmost issue. If these trends, combined with favorable government policies, continue to prevail, generic drugs will remain at the forefront of providing global healthcare.

Industry Segmentations

In terms of indication, the global drugs market is segmented into central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and others.

The global market is classified based on the route of administration, comprising oral, topical, parenteral, and others.

Depending on the distribution channel, the global generic drug market is divided into hospital, retail, and online pharmacy.

Regional Analysis

In North America, the generic drugs market is bolstered by the need to control rising healthcare costs. The US is the leader in the region with a vast network of manufacturers and a legal framework that is clearly defined and enables patent expiry and generic substitution. Patient acceptance of generics, which is growing, has made it possible to keep a strong sales record, especially in cardiovascular, oncology, and antibiotic segments. Canadian healthcare policies that promote cost efficiency are hence one of the factors that allow generics to be steadily taken up.

Europe's market is reaping the benefits from a regulatory environment that is clear and the presence of a strong public healthcare system that emphasizes affordability. Germany, Spain, and the UK are among the top consumers of this product, and their national health services are promoting generic prescriptions. The improvement in medicine accessibility, along with the increasing numbers of the middle-class population, are the main factors driving the catching up of Eastern European countries. Competitive pricing and supportive legislation are key growth factors in the region.

Asia-Pacific is the fastest-growing region, and most of the growth is coming from the manufacturing potential of Asia, particularly India and China. India is a global leader in supplying the highest quality generics at the most reasonable prices, and China's market is receiving the positive impact of healthcare reforms on a large scale. Due to demographic changes in the age structure of the population and rising prevalence of chronic diseases, the demand for cheap drugs has increased. Besides South Korea and Thailand, these countries are also among the most prolific users of generic medicine to reduce the cost of healthcare.

Latin America, the Middle East, and Africa are an increasing part of the generic medicines market on a global scale. With Brazil, there is a more aggressive push to increase local production, while Mexico benefits from cross-border trade with the US. Rising investment in pharmaceutical manufacturing in the Middle East is contributing to the region's effort to become more self-sufficient. African countries are setting the availability of drugs and the strengthening of distribution channels for generics as their top priorities.

Key Players

Major players in the global generic drugs market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Sun Pharmaceuticals Industries, Fresenius Kabi, Lupin Pharmaceuticals, Inc., Endo International plc, Aurobindo Pharma, Aspen Holdings, Cipla Ltd., and Fresenius SE & Co. KGaA.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE
  • 4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS
  • 4.2.3 RISING DEMAND FOR AFFORDABLE MEDICATIONS
• 4.3 RESTRAINTS
  • 4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS
  • 4.3.2 BRAND LOYALTY AND DOCTOR PREFERENCES
• 4.4 OPPORTUNITY
  • 4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE
  • 4.4.2 RISING AGING POPULATION

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET

6 GLOBAL GENERIC DRUGS MARKET, BY INDICATION

• 6.1 OVERVIEW
• 6.2 CENTRAL NERVOUS SYSTEM (CNS)
• 6.3 CARDIOVASCULAR
• 6.4 UROLOGY
• 6.5 ONCOLOGY
• 6.6 RESPIRATORY
• 6.7 OTHERS

7 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 7.1 OVERVIEW
• 7.2 ORAL
• 7.3 TOPICAL
• 7.4 PARENTERAL
• 7.5 OTHERS

8 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 8.1 OVERVIEW
• 8.2 HOSPITAL PHARMACY
• 8.3 RETAIL PHARMACY
• 8.4 ONLINE PHARMACY

9 GLOBAL GENERIC DRUGS MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITOR DASHBOARD
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCH
  • 10.6.2 PRODUCT LAUNCH / PRODUCT APPROVAL
  • 10.6.3 EXPANSION

11 COMPANY PROFILES

• 11.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 LUPIN PHARMACEUTICALS, INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 ENDO INTERNATIONAL PLC
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 AUROBINDO PHARMA
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 ASPEN HOLDINGS
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 CIPLA LTD
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 NOVARTIS AG
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 FRESENIUS SE & CO. KGAA
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 VIATRIS INC.
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES

12 DATA CITATIONS